Core Viewpoint - Collegium Pharmaceutical, Inc. has initiated an Accelerated Share Repurchase (ASR) agreement to repurchase $25 million of its common stock as part of a broader $150 million share repurchase program, reflecting a strategic approach to capital allocation while driving revenue growth and returning capital to shareholders [1][2]. Group 1: Financial Performance - In the first quarter of 2025, Collegium reported a 23% year-over-year revenue growth, attributed to strong sales from its pain management portfolio and significant contributions from its ADHD medication, Jornay PM® [2]. - The ASR agreement will initially deliver 692,281 shares to Collegium, based on a closing stock price of $28.89 on May 9, 2025, which represents approximately 80% of the total shares expected to be repurchased [2]. Group 2: Strategic Initiatives - The Board of Directors authorized the $25 million ASR as part of a disciplined capital allocation strategy aimed at sustaining revenue growth while also returning capital to shareholders [2]. - Collegium's strategy includes expanding its commercial portfolio with Jornay PM as a key growth driver and investing in business development while managing debt and share repurchases [2][3]. Group 3: Company Overview - Collegium Pharmaceutical is a diversified biopharmaceutical company focused on improving the lives of individuals with serious medical conditions, with a strong portfolio in pain management and a recent entry into neuropsychiatry through the acquisition of Jornay PM [3].

Collegium Pharmaceutical (COLL) reported $177.76 million in revenue for the quarter ended March 2025, representing a year-over-year increase of 22.7%. EPS of $1.49 for the same period compares to $1.45 a year ago.The reported revenue compares to the Zacks Consensus Estimate of $172.45 million, representing a surprise of +3.08%. The company delivered an EPS surprise of +4.20%, with the consensus EPS estimate being $1.43.While investors scrutinize revenue and earnings changes year-over-year and how they compa ...

Collegium Pharmaceutical (COLL) came out with quarterly earnings of $1.49 per share, beating the Zacks Consensus Estimate of $1.43 per share. This compares to earnings of $1.45 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 4.20%. A quarter ago, it was expected that this specialty pharmaceutical company would post earnings of $1.54 per share when it actually produced earnings of $1.77, delivering a surprise of 14.94%.Over the ...

Collegium Pharmaceutical (COLL) Q1 2025 Earnings Call May 08, 2025 04:30 PM ET Company Participants Ian Karp - Head of IRVikram Karnani - President & CEOScott Dreyer - Executive VP & Chief Commercial OfficerColleen Tupper - Executive VP & CFOLes Sulewski - VP - Biotech Equity Research Conference Call Participants Serge Belanger - Senior AnalystDavid Amsellem - Sr. Research Analyst Operator and welcome to the Collegium Pharmaceutical First Quarter twenty twenty five Earnings Conference Call. At this time, al ...

Q1 2025 Earnings Report May 8, 2025 | Nasdaq: COLL Healthier people. Stronger communities. Forward-Looking Statements This presentation contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. We may, in some cases, use terms such as "predicts," "forecasts," "believes," "potential," "proposed," "continue," "estimates," "anticipates," "expects," "plans," "intends," "may," "could," "might," "should" or other words that convey uncertainty of future events ...

Collegium Pharmaceutical (COLL) Q1 2025 Earnings Call May 08, 2025 04:30 PM ET Speaker0 and welcome to the Collegium Pharmaceutical First Quarter twenty twenty five Earnings Conference Call. At this time, all participants are in a listen only mode. A question and answer session will follow the formal presentation. Please note that this conference call is being recorded. I will now turn the call over to Ian Karp, Head of Investor Relations at Collegium. Thank you. You may begin. Speaker1 Thanks, Bria, and we ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-37372 Collegium Pharmaceutical, Inc. (Exact name of registrant as specified in its charter) Virginia (State o ...

Exhibit 99.1 Collegium Reports First Quarter 2025 Financial Results and Highlights Recent Company Progress – Generated Q1'25 Quarterly Net Revenue of $177.8 Million, Up 23% Year-over-Year – – Grew Jornay PM® Prescriptions by 24% Year-over-Year and Reported Quarterly Net Revenue of $28.5 Million; Jornay PM Prescribers Reached an All-Time-High – – Completed Jornay PM Field Force Expansion – – Generated Net Revenue of $149.2 Million from the Pain Portfolio, Up 3% Year-over-Year with All Three Core Products Rec ...

– Generated Q1’25 Quarterly Net Revenue of $177.8 Million, Up 23% Year-over-Year – – Grew Jornay PM® Prescriptions by 24% Year-over-Year and Reported Quarterly Net Revenue of $28.5 Million; Jornay PM Prescribers Reached an All-Time-High – – Completed Jornay PM Field Force Expansion – – Generated Net Revenue of $149.2 Million from the Pain Portfolio, Up 3% Year-over-Year with All Three Core Products Recording Revenue Growth in the Quarter – – Ended Q1’25 with Cash, Cash Equivalents and Marketable Securities ...

Wall Street expects a year-over-year decline in earnings on higher revenues when Collegium Pharmaceutical (COLL) reports results for the quarter ended March 2025. While this widely-known consensus outlook is important in gauging the company's earnings picture, a powerful factor that could impact its near-term stock price is how the actual results compare to these estimates.The earnings report, which is expected to be released on May 8, 2025, might help the stock move higher if these key numbers are better t ...